Edward Wijaya

2papers

2 Papers

9.6AIMar 30Code
What an Autonomous Agent Discovers About Molecular Transformer Design: Does It Transfer?

Edward Wijaya

Deep learning models for drug-like molecules and proteins overwhelmingly reuse transformer architectures designed for natural language, yet whether molecular sequences benefit from different designs has not been systematically tested. We deploy autonomous architecture search via an agent across three sequence types (SMILES, protein, and English text as control), running 3,106 experiments on a single GPU. For SMILES, architecture search is counterproductive: tuning learning rates and schedules alone outperforms the full search (p = 0.001). For natural language, architecture changes drive 81% of improvement (p = 0.009). Proteins fall between the two. Surprisingly, although the agent discovers distinct architectures per domain (p = 0.004), every innovation transfers across all three domains with <1% degradation, indicating that the differences reflect search-path dependence rather than fundamental biological requirements. We release a decision framework and open-source toolkit for molecular modeling teams to choose between autonomous architecture search and simple hyperparameter tuning.

QMFeb 10
Beyond SMILES: Evaluating Agentic Systems for Drug Discovery

Edward Wijaya

Agentic systems for drug discovery have demonstrated autonomous synthesis planning, literature mining, and molecular design. We ask how well they generalize. Evaluating six frameworks against 15 task classes drawn from peptide therapeutics, in vivo pharmacology, and resource-constrained settings, we find five capability gaps: no support for protein language models or peptide-specific prediction, no bridges between in vivo and in silico data, reliance on LLM inference with no pathway to ML training or reinforcement learning, assumptions tied to large-pharma resources, and single-objective optimization that ignores safety-efficacy-stability trade-offs. A paired knowledge-probing experiment suggests the bottleneck is architectural rather than epistemic: four frontier LLMs reason about peptides at levels comparable to small molecules, yet no framework exposes this capability. We propose design requirements and a capability matrix for next-generation frameworks that function as computational partners under realistic constraints.